Trofinetide

DRUG4 trials

Sponsors

ACADIA Pharmaceuticals Inc.

Conditions

Rett Syndrome

Phase 2

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome

TerminatedNCT04988867

ACADIA Pharmaceuticals Inc.Rett Syndrome

Start: 2021-09-22End: 2023-05-31Updated: 2024-09-24

Phase 3

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

CompletedNCT04181723

ACADIA Pharmaceuticals Inc.Rett Syndrome

Start: 2019-11-06End: 2021-10-28Updated: 2024-04-08

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

CompletedNCT04279314

ACADIA Pharmaceuticals Inc.Rett Syndrome

Start: 2020-01-29End: 2022-08-19Updated: 2024-04-11

Open-Label Extension Study of Trofinetide for Rett Syndrome

TerminatedNCT04776746

ACADIA Pharmaceuticals Inc.Rett Syndrome

Start: 2020-11-08End: 2023-06-30Updated: 2024-09-27

Related Papers

Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2–4 years with Rett syndrome

Med2025-03-044 citations

Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study.

2024-07-176 citations

Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study

Med2024-06-2425 citations

Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome.

2024-02-163 citations

A Plain Language Summary of Results from the LAVENDER Study: Trofinetide Treatment for Rett Syndrome

Future Rare Diseases2023-08-08

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

2023-06-08107 citations

Trofinetide for the treatment of Rett syndrome: an open-label study in girls 2 to 4 years of age (P13-9.005)

Neurology2023-04-255 citations

Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome

Contemporary Clinical Trials2022-02-0866 citations